The current financial score of Adaptive Biotechnologies Corp is 7.79. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 83.90M, representing a year-over-year decrease of 10.72%, while its net profit experienced a year-over-year decrease of 69.87%.
The current valuation score of Adaptive Biotechnologies Corp is 9.77. Its current P/E ratio is -87.20, which is -98.20% below the recent high of -1.57 and -6.65% above the recent low of -92.99.
The current earnings forecast score of Adaptive Biotechnologies Corp is 8.44. The average price target is 29.81, with a high of 35.00 and a low of 21.00.
The current price momentum score of Adaptive Biotechnologies Corp is 4.32. Currently, the stock price is trading between the resistance level at 30.08 and the support level at 24.85, making it suitable for range-bound swing trading.
The current institutional shareholding score of Adaptive Biotechnologies Corp is 10.00. The latest institutional shareholding proportion is 94.68%, representing a quarter-over-quarter decrease of 9.06%.
The current risk assessment score of Adaptive Biotechnologies Corp is 5.94. The company's beta value is 2.16. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.